The use of inhibiting cytokine-binding-proteins (CBPs) such as soluble cytokine receptors and anticytokine antibodies is considered for the treatment of cytokine-dependent diseases. The pleiotropic cytokine interleukin-6 (IL-6) is a target for immunointervention in numerous pathologic situations, including multiple myeloma, B-cell lymphoma, and rheumatoid arhtritis. An antitumor response was obtained in the treatment of a patient with multiple myeloma. A controversial issue is to evaluate whether the carrier effect of the CBPs might limit their efficiciency in blocking the target cytokine. We analyzed the pharmacokinetics of radiolabeled IL-6 in mice treated with various combinations of anti-IL-6 antibodies. We show that injection of one or two antibodies led to ) is a cytokine with pleiotropic effects on numerous physiologic IL-6 was shown to be the major growth factor for malignant plasma cells in murine and human plasmocytoma in ~i t r o~.~ and is involved in numerous pathologic situations, such as Kaposi's sarcoma,' osteoporosis,s renal cell carcinoma: and prostate carcinoma." Anti-IL-6 monoclonal antibodies (MoAbs) or anti-IL-6 receptor antibodies are effective in the treatment of experimental diseases in mice.6*1'.12 These observations led to a clinical trial using anti-IL-6 MoAb in a myeloma patient with terminal disease13 and, more recently, in rheumatoid arthriti~.'~ An antitumor response was obtained in multiple myeloma, as evidenced by the decrease in the serum level of the paraprotein. The effectiveness of IL-6 inhibition was shown by the complete inhibition of the production of the serum C-reactive protein (CRP), which was previously shown in vitro to be dependent on IL-6." In some myeloma patients who did not respond to anti-IL-6 MoAb therapy, CRP production was only partielly blocked.'6 During the treatment with anti-IL-6 MoAb, we observed the accumulation of IL-6 in the serum in the form of monomeric immune c~mplexes.'~ Similar observations were made in animal models of mice treated with IL-6 antib~dy.".'~ The accumulation of IL-6 in the form of monomeric immune complexes might be a major limitation of the efficiency of MoAb-based therapy, especially when IL-6 is produced at a high level. These results prompted us to analyze the pharmacokinetics of anti-IL-6 therapy with MoAbs in an animal model.
NTERLEUKIN-6 (L-6) is a cytokine with pleiotropic effects on numerous physiologic IL-6 was shown to be the major growth factor for malignant plasma cells in murine and human plasmocytoma in ~i t r o~.~ and is involved in numerous pathologic situations, such as Kaposi's sarcoma,' osteoporosis,s renal cell carcinoma: and prostate carcinoma." Anti-IL-6 monoclonal antibodies (MoAbs) or anti-IL-6 receptor antibodies are effective in the treatment of experimental diseases in mice.6*1'.12 These observations led to a clinical trial using anti-IL-6 MoAb in a myeloma patient with terminal disease13 and, more recently, in rheumatoid arthriti~.'~ An antitumor response was obtained in multiple myeloma, as evidenced by the decrease in the serum level of the paraprotein. The effectiveness of IL-6 inhibition was shown by the complete inhibition of the production of the serum C-reactive protein (CRP), which was previously shown in vitro to be dependent on IL-6." In some myeloma patients who did not respond to anti-IL-6 MoAb therapy, CRP production was only partielly blocked.'6 During the treatment with anti-IL-6 MoAb, we observed the accumulation of IL-6 in the serum in the form of monomeric immune c~mplexes.'~ Similar observations were made in animal models of mice treated with IL-6 antib~dy.".'~ The accumulation of IL-6 in the form of monomeric immune complexes might be a major limitation of the efficiency of MoAb-based therapy, especially when IL-6 is produced at a high level. These results prompted us to analyze the pharmacokinetics of anti-IL-6 therapy with MoAbs in an animal model.
We have measured the clearance of radiolabeled human IL-6 in mice treated with either one or with several murine antibodies of very high affinity for human IL-6. In animals injected with a single MoAb, the mean residence time of L -6 in plasma is 10 times higher than that in untreated animals, thus leading to a dramatic stabilization of the cytokine. Similar results were obtained with animals treated with two anti-IL-6 antibodies. Surprisingly, in animals treated with a combination of three antibodies binding three distinct epitopes, the clearance of IL-6 was very much enhanced. We showed that this enhancement was mediated by the capture of immune complexes by the receptors for the Fc domain of IgG (Fc receptors), mainly by liver cells. The ternary immune complexes have an enhanced affinity for Fc receptors caused by cyclization and resulting multiple binding, leading to a new route of elimination of these complexes. The use of cocktails of three MoAbs, recognizing three distinct epitopes of a cytokine, provides a new means of antagonizing cytokine activity in vivo.
918

MONTERO-JULIAN ET AL
analytical grade and purchased from Merck (Darmstadt, Germany). Cell culture reagents were from Flow (Irvine, UK). The buffer designated as PBS-BSA is phosphate-buffered saline (PBS; pH 7.4, containing 20 mmol phosphate, 2 mmol NaN1, 0.15 mol NaCI) and 20 g of bovine serum albumin (BSA; Boehringer Manheim, Manheirn, Germany) per liter. Purified recombinant Escherichia coli-derived human IL-6 was obtained from CLB (Amsterdam, The Netherlands).
Epitope analysis. The definition of the epitopes recognized by the different anti-IL-6 MoAbs was performed in IL-6 enzymelinked immunoassays (ELISAs), using various antibodies as solid phase and tracer. Antibodies were biotinylated with biotin-N-hydroxy-succinimide-l-ester (Boehringer Mannheim) following the manufacturer's instructions. First, 96-well microtiter plates (Nunc, Roskilde, Denmark) were coated with a 10 pg/mL solution of anti-IL-6 antibody in PBS and blocked with PBS containing 30 g/L of BSA. The immunoassay was then performed as follows. One hundred microliters of IL-6 solution (1 ng/mL) diluted in PBS-BSA were incubated in coated wells together with 100 pL of biotinylated antibody ( I pg/mL) for 8 to 12 hours at +4"C . The plates were then washed twice with PBS containing 0.5 g/L of Tween 20 and bound biotinylated antibodies were shown with peroxydase-conjugated streptavidin (Jackson, West Grove, PA). The absorbance of the enzyme substrate was determined at 492 nm using an automatic plate reader (SLT, Salzburg, Austria).
Radiolabeling of IL-6. Iodination was performed by the standard chloramine-T method. Briefly, to 2 pg of IL-6 at 0.1 mg/mL in PBS was added 5 pL (0.5 mCi) of "'NaI (Amersham, Amersham, UK) and 10 pL of a 1 mg/mL solution of chloramine-T in PBS. The reaction mixture was incubated for 1.5 seconds at 20°C. The reaction was then quenched by the addition of 50 pL of 50 mmol/L glycyltyrosine (Bachem, Bubendorf, Switzerland) and 0.5 mL of PBS-BSA. Separation of proteins and low molecular weight reactants was achieved by gel filtration chromatography with Sephadex G50 (Pharmacia, Uppsala, Sweden). Higher molecular weight fractions containing aggregates were discarded. The material corresponding to the IL-6 peak was diluted in PBS-BSA and stored for up to I month at 4°C. The preparation gave a single 22.5-kD radioactive band in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and more than 90% of the total radioactive material could be precipitated by trichloroacetic acid (TCA). The specific radioactivity, determined with a commercial ELISA (Immunotech, Marseille, France), was always in the range of 0.6 to 0.8 X IOl4 cpm/mol. The reactivity of '"1-IL-6 with the four anti-IL-6 antibodies was tested in a liquidphase binding assay using polyethylene-glycol precipitation for separation of bound and free Iz5I-IL-6. More than 75% of labeled IL-6 was precipitated by each anti-IL-6 antibody in all experiments.
In vivo tests. Female, 6-to 8-week-old Balb/c mice were obtained from CERJ (Laval, France). The mice were maintained in a specific pathogen-free facility for a minimum of 2 weeks before use. Eighteen hours before the experiment, the animals were injected intravenously (IV) via the lateral tail vein with 50 pL of either anti-IL-6 antibody solution or isotonic salt solution under mild ether anesthesia. The total dose of antibody injected was 5 pg, regardless of the combination of anti-IL-6 antibodies used. The mice were then injected IV with 50 pL of radiolabeled 1L-6 (IO7 cpm/mL) under the same conditions. Blood samples (approximatly 50 pL) were collected at several time intervals and stored at + 4 T . The samples were centrifuged for 5 minutes at 4,OOOg and the radioactivity of 3 pL of serum was determined. Preliminary experiments indicated that there was no significant radioactivity associated with the cell pellet. The 24-hour urines were also collected and their radioactivity determined. All pharmacokinetic experiments were performed simultaneously with three animals for each treatment. For biodistribution studies, injected animals were killed with ether at several time intervals. Hearts were incised and the blood was collected with heparin and centrifuged for 5 minutes at 4,0008. The animals were weighed and the major organs were dissected. Radioactivity was determined in 100-pL samples of plasma and in dissected organs. Plasma samples were stored at -80°C until fractionation by gel filtration chromatography.
Gel filtration chromatography. Gel filtration chromatography was performed using a Sephacryl S400 HR 16/100 and an FPLC system (both from Pharmacia). The column was calibrated with the following molecular weight standards: thyroglobulin (669 kD), ferritin (440 kD), catalase (232 kD), aldolase (158 kD), BSA (67kD). ovalbumin (45 kD), and chymotrypsinogen A (25 kD) (calibrators from Pharmacia). Serum samples from treated mice were centrifuged, filtered (0.22-pm Micropacks from Millipore, Milford, MA) and 200 pL was applied and eluted with PBS at 1 mL/min. Fractions of 1 .S mL were collected and tested for their radioactivity.
Datu analysis. In in vivo studies, data were expressed as the percentage of injected dose (%ID) localized in a given organ and also, so as to allow comparison between organs in biodistribution studies, as the percentage of injected dose per gram of tissue (%ID/ g). Radioactivity of the gut and of its contents was determined together. Plasma was evaluated as 0.047 mL/g of body weight. Data on relative organ weights in mice were taken from Covell et aLZ2
In pharmacokinetic experiments, the percentage of the injected dose was plotted as a function of time for each treatment. The initial pharmacokinetic parameters were obtained by fitting the experimental data to a two-compartment model using a biexpenonential equation %ID([) = a1.e-l" + a2e"", with a weight of l /~. Clearance, distribution volumes, and residence times were derived from the initial parameters al,a2, I1 ,l2 according to Webster et al."
Binding assays. The mouse macrophage cell line P388DlZ4 was maintained in RPM1 1640 supplemented with 10% vol:vol fetal calf serum, 2 mmol/L glutamine, 1% vol:vol nonessential amino acids (loox), 1% vol:vol pyruvate (0.1 mol/L), and 1% v01:vol penicilinstreptomycin (5,000 U/mL). Cells were detached mechanically, washed twice with PBS-BSA, and resuspended in the same buffer at IO7 cells/mL. Binding experiments were performed as described by Dower et al? 100 pL of the cell suspension, 100 pL of anti-IL-6 antibody solution (either I , 2, or 3 MoAbs), and 150 p L of radiolabeled IL-6 (lOhcpmimL), all in PBS-BSA containing 2 mmoll L NaN3, were incubated in a 96-well microtiter plate. After 2 hours at +37"C under agitation, 100 pL of the suspensions was centrifuged for 30 seconds at 10,OOOg through a phtalate-oil mixture. The bottom of the tube, containing the cell pellet, was cut out and its radioactivity was determined. Nonspecific binding was determined in the absence of anti-IL-6 MoAb and subtracted from bound radioactivity.
RESULTS
Epitope mapping.
Immunoassays were performed with all possible combinations of two at a time of the following MoAbs: AH64, AH65, BE4, and BE8. The signal pattern observed indicated that the four antibodies belonged to three distinct groups: (1) AH6.5, (2) BE4, and (3) a third group comprising AH64 and BE8. So as to confirm that these experiments defined three distinct epitopes, we performed immunoassays with a third MoAb present in excess in solution.
In immunoassays in which we used solid-phase and tracer antibodies of two different groups, we did not observe any interference by a third antibody from a third group. We confirmed in gel filtration experiments that three different MoAbs, recognizing three distinct epitopes as defined above, bound simultaneously to 12s1-IL-6 and formed stable ternary Eighteen hours before the experiment, mice were treated with anti-IL-6 antibody AH65 (1 Ab), combinations of anti-IL-6 Abs AH65 + BE8 (2 Abs), AH65 + BE8 + BE4 (3 Abs), or saline. The total dose of antibody injected was 5 pg. Results were expressed as percentage of injected dose in plasma versus time. The data were then analyzed as described in Klein et From the fitted parameters of the curve [%ID(t) = al.e"I1
+ a2e-In1, we calculated the half-lives T n and TB of the two phases of elimination; the first and second momentum area under the curve (AUC)
and area under the moment curve (AUMCI; the initial dose in plasma (CO); the clearance (CL); the mean residence times in the central compartment (MRTc), in the periphery (MPRTp), and in the body (MRTb); the steady-state distribution volume (Vss); and the plasma volume (Vp).
immune complexes of about 500 kD (see Fig 2A) . In the same experiments, we observed that 25% to 30% of I2'I-IL-6 was in the form of lower molecular weight complexes corresponding to monomeric and dimeric immune complexes. In fact, the maximal binding of '*'I-IL-6 to each of the three MoAbs was 75% to 85% in a liquid-phase assay. This partial reactivity of the labeled IL-6 with each antibody of the combination results in the formation of monomeric/ dimeric complexes even in the simultaneous presence of excess amounts the three MoAbs.
Pharmacokinetics of radiolabeled IL-6. The experimental curves were fitted with a biexponential using a l/y weighting, which gives the best possible fit (Table 1) . Fitting with a three-exponential did not lead to better results. The pharmacokinetic parameters were calculated from the coefficients of the biexponential. In all cases, the elimination may be considered as biphasic, which corresponds to a twocompartment model with a distribution phase and an elimination phase (beta phase). In control, untreated animals, radiolabeled IL-6 had a short residence time of about 70 minutes in the central compartment and a rapid clearance (2.37 mL/ h). Conversely, the residence time of radiolabeled IL-6 increased to 522 minutes in animals treated with any of the four anti-IL-6 MoAbs and the clearance was 15-fold slower (0.16 mwh). Similar results were obtained in animals treated with a pair of monoclonals (clearance, 0.22 m w h ; mean residence time in plasma, 724 minutes). Not surprisingly, the steady-state distribution volume of monomeric immune complexes was fivefold lower than the steady-state distribution volume of IL-6 in untreated mice. In fact, the diffusibility of the molecule reflects the differences in the molecular weights. In mice treated with BE4 + BE8 + AH65, the clearance of IL-6 (1.60 m u h ) was almost as rapid as the clearance of IL-6 in untreated animals. The mean residence time in the central compartment was 83 minutes. These results suggested that trimeric immune complexes were eliminated preferentially. We used other combinations of MoAbs as intrinsic controls. The treatment of the animals with the four MoAbs recognizing three distinct epitopes led to similar results. In this case, only three MoAbs can bind simultaneously to IL-6, because BE8 and AH64 were shown to comPete with each other. Conversely, combinations of three antibodies containing two competitive antibodies, such as BE4 + BE8 + AH64, behaved like combinations of two different antibodies.
Biodistribution of radiolabeled IL-6. In biodistribution experiments, the data obtained for the plasma compartment confirmed the pharmacokinetic analysis (Fig 1) . The elimination of radiolabeled IL-6 was rapid in untreated animals and in animals treated with a combination of three MoAbs. It was much slower in animals treated with one or two anti-IL-6 antibodies. Mean residence times (MRTs) in the central compartment were calculated from this new set of data. (We found MRTs of 70, 600, and 70 minutes for control mice, mice treated with one antibody, and mice treated with three antibodies, respectively.) In untreated animals, there was no specific localization of IL-6 in any organ. More than 70% of the injected radioactivity was detected in the urine of the animals, indicating that the molecule was eliminated by renal filtration. In animals treated with one or two anti-IL-6 antibodies, we also did not observe accumulation of IL-6 in any organ. In contrast with these results, a striking accumulation of radioactivity occured in the livers of animals treated with combinations of three antibodies recognizing distinct epitopes of IL-6.
Gel jiltration chromatography of serum samples. Gel Fig 2) . Thus, the technique could be used for further analysis of the molecular form of circulating complexes in treated and untreated mice. In plasma samples from untreated animals injected with radiolabeled IL-6, 85% of the radioactivity was detected in fractions corresponding to molecules of 25 to 30 kD. Conversely, the gel filtration chromatography of plasma samples from animals treated with one anti-IL-6 MoAb indicated that the major form, detectable in the plasma, consisted of monomeric complexes of about 180 kD. Thus, the formation of monomeric immune complexes was responsible for the stabilization of the circulating cytokine. Similarly, complexes of 350 kD were detected in the serum of animals treated with pairs of anti-ll-6 MoAbs. Trimeric complexes of higher molecular weight were detected in plasma samples spiked in vitro with labeled IL-6 and a combination of three complementary anti-IL-6 antibodies and could be also detected in the plasma of animals treated with the same combination, 5 minutes after IL-6 injection. However, the total amount of radioactive material in this sample was much lower than serum samples from the mice treated with one or two antibodies. One hour after the injection, the peak corresponding to trimeric complexes was no longer detectable. In these plasma samples, the radioactivity was detected in fractions of lower molecular weight corresponding to monomeric and dimeric immune complexes. These experiments confirmed that trimeric immune complexes were eliminated very rapidly. The residual radioactivity in mouse sera corresponded to the monomeric and dimeric complexes formed as a result of the partial reactivity of labeled IL-6 with the three antibodies. The pharmacokinetic analysis led, in fact, to an overestimation of the residence time of IL-6 in animals treated with three antibodies, because the calculation from experimental data took into account the contribution of monomeric and dimeric complexes. The gel filtation experiments suggest that the mean residence time of trimeric complexes in the central compartment was much lower than 84 minutes and was, in fact, close to 5 minutes.
Rirtding of immune complexes to Fc receptors. First, we analyzed the binding of labeled human IL-6 to the membrane of the murine macrophage P388D1 cells in the presence of murine anti-IL-6 antibodies. Labeled IL-6 was used at a concentration of about 1 nmol/L. There was no significant membrane binding either in the absence of anti-IL-6 MoAb or in the presence of a single antibody, of either IgGl isotype (AH@, AH65, or BE@, or of IgG2b isotype (BE4). We tested next the effect of different MoAb combinations at the same total antibody concentration. Only combinations comprising three antibodies, recognizing distinct epitopes of IL-6, precipitated labeled IL-6 onto the membrane (Fig 3) . Some binding was observed when two antibodies were added. Preincubation of labeled 1L-6 with the anti-IL-6 MoAbs before the membrane binding experiment had no effect on the result. Interestingly, the binding of radiolableled IL-6 to P388DI cells was completely abrogated in the presence of anti-FcRy MoAb 2.462 at I O pg/mL, demonstrating that the binding resulted from the interaction of the constant parts of the Ig immune complexes with the membrane Fc receptor and not from a direct interaction of IL-6 with membrane IL-6 receptors. In a second experiment, we determined the dose-response curve of membrane binding. Half-maximal binding of labeled IL-6 occurred at a total concentration of antibody of 4 ng/mL for the combination (AH64 + BE4 + BES), ie, an antibody concentration of approximatly 25 pmol/L. Finally, we tested the effect of competing irrelevant mouse Igs the binding of IL-6-containing immune complexes. The membrane binding of trimeric immune complexes was not affected by irrelevant mouse Igs at 1 mg/mL, whereas the binding of dimeric complexes was completly abolished at this concentration of competitor.
DISCUSSION
There are numerous pathologic situations that may benefit from a specific means of antagonizing a cytokine response in vivo, such as, eg, septic shock and acute inflammatory diseases, cytokine-dependent tumor growth, and reaction to organ transplantati~n.~~~" Cytokine-binding proteins (CBPs), such as soluble cytokine receptors'' or immunoadhesins comprising fragments thereof:9 have been considered for this purpose, as have anticytokine MoA~s.".'~ Such CBPs might be very useful in specifically counteracting the deleterious effects of cytokine overproduction associated with a pathologic situation. MoAbs are of special interest, because high-affinity antagonists can be produced readily. The present study was designed to investigate the pharmacokinetics of antibody-based anticytokine therapy.
Cytokines were shown to have a very short residence time in vivo. In rats, IL-6 was shown to be cleared rapidly from the plasma by binding to cell surface receptors (mainly in the liver) and by renal filtration, and then to accumulate transiently in the The plasma half-life of IL-6 was 20 minutes. We have determined the pharmacokinetic parameters for IL-6 using radiolabeled human IL-6 injected into mice. The mean residence time of IL-6 in the central compartment computed from our experimental data (70 minutes, Table 1 ) was significantly greater than that reported previously." We found a significant contribution of the beta phase in the elimination of IL-6 from the central compartment. We did not detect any transient accumulation of IL-6 in the skin, or in any other organ; most of the radioactivity accumulated in the urine, indicating that renal filtration was the major route of elimination. It should be noted that L -6 of human origin might behave differently from the autologous murine molecule in its interaction with soluble or membrane receptors.
We had previously shown the accumulation of IL-6 in the form of monomeric immune complexes in patients treated with anti-IL-6 antibody." The present data from the mouse model indicate that the mean residence time of IL-6 in animals treated with anti-IL-6 antibody is of the same order of magnitude as the mean residence time of the injected antibody," thus providing a direct pharmacokinetic explanation for IL-6 accumulation. When the total concentration of IL-6 in the plasma increases, IL-6 becomes available to those cells expressing the highest number of IL-6 high-affinity receptors, which displace competitively IL-6 bound to anti-IL-6 antibody. Hence, the accumulation of immune complexes results in the increase of bioavailable IL-6 and may severely limit the therapeutic use of anti-IL-6 antibodies. These results are consistent with the earlier paradoxical observation that the protective effect of anti-IL-6 antibodies in animal models of septic shock correlated with an increase of bioavailable IL-6.'9.32 Antibodies provide a model for the analysis of the physiology of CBPs such as soluble cytokine receptors. As suggested by several recent reports, antagonist CBPs, including MoAbs, may act in vivo as camers for their respective ligands. '8,33-3s In contrast with the stabilization observed with one or with two anti-IL-6 antibodies, the clearance of IL-6 increased least 15-fold in animals treated with a combination of three antibodies that bound simultaneously to IL-6 and formed trimeric immune complexes. What is the mechanism underlying this striking effect? First, all antibodies used in our study had high affinity for IL-6 (Kd, 5 to 10 pmoVL measured at +4"C), leading to very stable complexes with IL-6 (dissociation half-time, >72 hours; F.A.M.-J., unpublished observations). Second, all anti-IL-6 MoAbs were blocking MoAbs, which totally inhibited the binding of IL-6 to its high-affinity receptor at the concentration used in vivo. Thus, significant dissociation of the immune complexes could not occur during the in vivo experiments and the mem-MONTERO-JULIAN ET AL brane binding of complexed 1L-6 was not dependent on antigen-antibody interaction nor on interaction of IL-6 with high-affinity IL-6 receptors. Membrane binding of trimeric immune complexes occurred at low concentrations of three complementary antibodies, but was not significant with only two antibodies able to bind simultaneously to the cytokine. Moreover, the binding of trimeric immune complexes was not affected by high concentrations of irrelevant monomeric antibodies, but was completly abolished by anti-Fc receptor antibody. We may assume then that the high-affinity binding of trimeric immune complexes was caused by multiple binding of the Fc part of the antibody to membrane Fc receptors. The binding equilibrium and the binding kinetics of immune complexes of defined stoichiometry to Fc receptors have been analyzed previously using the model of a multivalent hapten and an antihapten antibody.3h The results indicated that dimeric and trimeric immune complexes bound preferentially to antigen-presenting cells."~" even in the presence of high concentrations of competitive irrelevant monomeric antibodies,"' and were cleared more rapidly from the circulat i~n .~' In another model, a similar affinity enhancement effect was shown to occur in vitro" and in vivo.4' In animals treated with three antibodies, we observed the accumulation of the radiolabeled IL-6 in the liver immediately after the injection. The liver Kupffer cells were previously reported to be the major site of elimination of soluble immune complexes.44 Taken together, our results suggest that the enhancement of the clearance of IL-6 in the presence of three antibodies, binding to distinct epitopes, is caused by selective uptake of trimeric complexes by Fc receptors of the cells of the endoreticulum compartment, providing a new route for the elimination of IL-6 in vivo. We observed a striking difference in clearance and in membrane binding between dimeric and trimeric immune complexes that had not been observed in earlier studies with multivalent haptens. The structural basis for these differences remains to be clarified. Complexes of higher order should be tested; however, we failed to identify four MoAbs able to bind simultaneously to 1L-6. The respective contribution of the different Fc receptor isotypes, as well as the respective efficiencies of the different antibody isotypes, also remains to be investigated. The production of hybrid human-murine antibodies comprising a constant region of human origin of any isotype is now routine laboratory p r a~t i c e~' .~~ and such hybrids may be considered for the clinical use of anticytokine antibody cocktails.
The modification of the route of elimination of the target molecule may have adverse physiologic effects. FcR crosslinking by trimeric immune complexes may lead to the activation of antigen-presenting cells and to the stimulation of the production of monokines, including IL-6 itself.47 However, in most cases, the amount of the trimeric complexes to be eliminated is very low compared with the average normal concentration of immune complex in the plasma, which is approximately 10 pg/mL.4* In myeloma patients, the production of IL-6 was found to average I O pglday." Conversely, in a patient suffering from sepsis, the daily IL-6 production was greater than 7 mgdy and in such extreme cases, the quantity of trimeric complexes may limit the use of MoAbs cocktails.
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The present study shows that cytokine-binding proteins have dramatic effects on cytokine pharmacokinetics. These pharmacokinetic phenomena have to be taken into account in the evaluation of potential antagonists, such as soluble cytokine receptors. Specifically, the phenomenon of stabilization of a cytokine by a cytokine-binding molecule might be a strong limitation to the therapeutic efficiency of cytokinebinding antagonists, thus leading to much higher active doses in vivo than those predicted from in vitro pharmacologic studies. The use of a cocktail of three antibodies, binding simultaneously to a cytokine, provides a new means of enhancing the clearance of the target molecule and should help in the design of antibody-based clinical trials by overcoming the problem of the accumulation of monomeric immune complexes. More generally, it should prove possible to manipulate the clearance of a cytokine in vivo and thus to gain information regarding physiologic processes involved in the regulation of the cytokine response.
